In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
about
Dihydroartemisinin/Piperaquine: a review of its use in the treatment of uncomplicated Plasmodium falciparum malariaeditAntimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR NetworkAntimalarial efficacy of piperaquine-based antimalarial combination therapies: facts and uncertaintiesRecent advances in malaria drug discoveryA HECT ubiquitin-protein ligase as a novel candidate gene for altered quinine and quinidine responses in Plasmodium falciparumPolymorphisms in K13 and Falcipain-2 Associated with Artemisinin Resistance Are Not Prevalent in Plasmodium falciparum Isolated from Ugandan ChildrenTemporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in UgandaProtective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trialEfficacy and day 7 plasma piperaquine concentrations in African children treated for uncomplicated malaria with dihydroartemisinin-piperaquineA potent antimalarial benzoxaborole targets a Plasmodium falciparum cleavage and polyadenylation specificity factor homologueMalaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts.High-throughput analysis of antimalarial susceptibility data by the WorldWide Antimalarial Resistance Network (WWARN) in vitro analysis and reporting tool.A Variant PfCRT Isoform Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug PiperaquineEx vivo anti-malarial drugs sensitivity profile of Plasmodium falciparum field isolates from Burkina Faso five years after the national policy changePolymorphisms in Pfmdr1, Pfcrt, and Pfnhe1 genes are associated with reduced in vitro activities of quinine in Plasmodium falciparum isolates from western KenyaEx vivo susceptibility and genotyping of Plasmodium falciparum isolates from Pikine, SenegalSelection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina FasoComparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan childrenPlasmodium falciparum isolates from Angola show the StctVMNT haplotype in the pfcrt gene.Differential prevalence of transporter polymorphisms in symptomatic and asymptomatic falciparum malaria infections in Uganda.In vitro piperaquine susceptibility is not associated with the Plasmodium falciparum chloroquine resistance transporter geneIn vitro antimalarial susceptibility and molecular markers of drug resistance in Franceville, GabonLimited ability of Plasmodium falciparum pfcrt, pfmdr1, and pfnhe1 polymorphisms to predict quinine in vitro sensitivity or clinical effectiveness in UgandaEfficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.Efficacy and safety of fixed-dose artesunate-amodiaquine vs. artemether-lumefantrine for repeated treatment of uncomplicated malaria in Ugandan childrenIn vivo selection of Plasmodium falciparum Pfcrt and Pfmdr1 variants by artemether-lumefantrine and dihydroartemisinin-piperaquine in Burkina Faso.Multinormal in vitro distribution of Plasmodium falciparum susceptibility to piperaquine and pyronaridine.Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.Discordant temporal evolution of Pfcrt and Pfmdr1 genotypes and Plasmodium falciparum in vitro drug susceptibility to 4-aminoquinolines after drug policy change in French GuianaIdentification of large variation in pfcrt, pfmdr-1 and pfubp-1 markers in Plasmodium falciparum isolates from Ethiopia and Tanzania.Ex vivo activity of the ACT new components pyronaridine and piperaquine in comparison with conventional ACT drugs against isolates of Plasmodium falciparum.Lack of Artemisinin Resistance in Plasmodium falciparum in Uganda Based on Parasitological and Molecular AssaysVariable piperaquine exposure significantly impacts protective efficacy of monthly dihydroartemisinin-piperaquine for the prevention of malaria in Ugandan children.Assessing the cost-benefit effect of a Plasmodium falciparum drug resistance mutation on parasite growth in vitro.In vitro sensitivities of Plasmodium falciparum isolates from the China-Myanmar border to piperaquine and association with polymorphisms in candidate genes.Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in NigerAnti-malarial prescription practices among outpatients with laboratory-confirmed malaria in the setting of a health facility-based sentinel site surveillance system in Uganda.Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance alleles in Ghanaian Plasmodium falciparum isolates after the change of anti-malarial drug treatment policy.
P2860
Q21032449-51726251-1B3C-408C-A994-639F945AE2FEQ26799713-EC5A3500-6884-4846-97E4-A4BF279B3885Q26866187-5880F049-673B-4B48-9F6A-40537B8428D9Q27010534-C0E14B39-0CE0-4D3D-92F0-0D6A4B1E62EFQ27861949-5457CC47-2212-4347-8EA8-F80EA78677F5Q27861962-898B2C6B-BDA4-46D9-A806-5807DA7BFF7CQ28125904-333CB991-1295-42D1-9069-4A80374856C9Q28541598-365844C4-E2A1-4CE8-936C-A95F080E1DB0Q28542034-DE032AB1-482C-4384-8CED-1345BAEB436DQ30045921-355452BA-DE75-4BD0-B86D-9ACAE22A0646Q30226671-7608617C-263C-4FA3-8EEB-67BDF2B52727Q30619647-41CFF6D3-EE1C-44E8-B316-770F7F921645Q33654512-AB2A5716-62DF-4912-9868-DE568ADFDCACQ33726272-56B22F44-2BDE-4612-9A8C-B358E782E59AQ33798486-84254A8A-A700-417F-821B-10F95EE2E145Q33802071-E2439917-ECF8-4D9E-A4D1-A00940098647Q33826359-C431E22F-EF69-41FF-AD8A-A13C08AFB832Q33947834-B059E647-0E33-4F1A-BCCA-1C68019FC2FCQ33968854-A6399C8B-475E-487D-A1C7-F2A261EAB033Q34169765-D238B1DF-B82A-4967-B2BF-30A01CF49AA0Q34478084-E3399C22-B095-497B-A0F1-EF7A400ABBCAQ34478362-78F2C53B-5AD6-4181-8507-635B37F75F97Q34529355-9B67FC89-B1B9-4CFF-93DA-B43D5107DC93Q34562333-0065AABC-FB37-4EBC-9255-747E40D8A5AEQ34600201-086E123B-DDA4-48DB-A6C0-3DEE3B2F86E1Q34923315-E4820E1B-AA60-487A-9B42-27FE01C6452DQ35068138-63F9F61D-1F70-4B01-8FE4-2A831F2EBA49Q35188480-82A6C86E-75A7-4F22-A97D-C7F816F479FFQ35607844-B7E9FACC-CD60-4899-B12F-E6CE294E1017Q35806342-D4868A7A-4509-49C0-962D-31EBA90002DEQ35830639-D0B887D3-379B-4BDA-9E13-C7744963CDB6Q35834198-48EC8A58-10A0-41A7-9627-641816FDE3B7Q35860091-1834CC0B-E43C-4343-8D0F-279EC3809670Q36092227-5C2014BD-BD9C-4EBF-8CA4-42E05291E3DBQ36558529-868073F0-F808-4B7B-9C90-437528DE6D5BQ36757694-639BDAD6-8908-4F63-9C3D-3DCBAAE8676EQ36876420-60B41B28-63BA-44F6-9817-C64595AA29CBQ36969710-3D5A1251-C10D-4DC9-9AF0-B283EC73C4C3Q37045375-91A6F3E6-42F4-4986-A9FF-A2CB3062D416Q37285721-571D63CC-D10B-4875-A2F6-C8A860CB04E8
P2860
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@ast
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@en
type
label
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@ast
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@en
prefLabel
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@ast
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@en
P2093
P2860
P50
P921
P356
P1476
In vitro sensitivities of Plas ...... antimalarial drugs in Uganda.
@en
P2093
Moses Kiggundu
Samuel L Nsobya
Sarah Nanyunja
P2860
P304
P356
10.1128/AAC.01412-09
P407
P577
2010-01-11T00:00:00Z